drugset

drugset / Trial / NCT01255592

Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis

NCT01255592 ↗

Phase 2 Completed 83 enrolled AstraZeneca

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate the effect of AZD5069 in patients with bronchiectasis.

Timeline

Start: 2011-02
Primary completion: 2012-02
Completion: 2012-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD5069	Small molecule	—	Oral

Indications